Pure Global
NCT05545280

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine or Sugammadex

Postoperative Urinary Retention in Hip and Knee Surgery After Reversal of Neuromuscular Block by Neostigmine or Sugammadex: A Randomized Controlled Trial
The Cleveland Clinic·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neuromuscular Blockade
Drug/Device/Intervention
Neostigmine with glycopyrrolate
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Cleveland Clinic
Location
Cleveland, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Dec 01, 2022
End date
Feb 01, 2025
Enrollment
286 participants
Primary outcome

Urinary retention

Summary

The investigators propose a randomized trial comparing sugammadex and neostigmine for the
 reversal of neuromuscular blocks induced by rocuronium or vecuronium in adults having general
 anesthesia with muscular block for hip and knee orthopedic surgery.

ICD-10 classifications
Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05545280
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05545280 through Pure Global AI's free database. This Phase 4 trial is sponsored by The Cleveland Clinic and is currently Not yet recruiting. The study focuses on Neuromuscular Blockade. Target enrollment is 286 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.